Daniel Lynch, MD
Interventional Pain Medicine · Louisville, KYNPI 1922027705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $711 and has fallen 81.0% since, to $135 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in KY, where the typical reported total is $3,169.
Across 114 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$556
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$349
- Si-bone, Inc.$312
- Stryker$177
- Pfizer$168
- GRT US Holding, Inc.$154
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,785100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 21 | $556 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $349 |
| Si-bone, Inc. | 7 | $312 |
| Stryker | 2 | $177 |
| Pfizer | 12 | $168 |
| GRT US Holding, Inc. | 9 | $154 |
| AbbVie(2 entities) | 2 | $143 |
| MDD US Operations, LLC | 2 | $134 |
| AstraZeneca | 1 | $92 |
| Acadia Pharmaceuticals Inc | 1 | $85 |
| Arbor Pharmaceuticals, Inc. | 5 | $67 |
| Boston Scientific | 3 | $63 |
| Pacira Therapeutics, Inc. | 3 | $57 |
| Scilex Pharmaceuticals Inc. | 4 | $55 |
| Neurocrine Biosciences, Inc. | 1 | $54 |
| Averitas Pharma Inc. | 2 | $43 |
| Redhill Biopharma Inc. | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Merck | 2 | $34 |
| Amgen | 2 | $29 |
| Bioventus LLC | 1 | $21 |
| Vertex | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| GSK | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Stimwave Technologies Incorporated | 1 | $13 |
| Novo Nordisk | 1 | $12 |
| Zimmer Biomet | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
- Lucemyra/Lofexidine$124
- PANGEA$121
- SYNCHROMEDII$120
How this compares
$2,785 in reported general payments places this provider in the 45th percentile of 55 interventional pain medicine providers in Kentucky.
See all interventional pain medicine providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 73 | $175,401 |
| MovantikNaloxegol Oxalate | 26 | $10,453 |
| Lidocaine | 143 | $10,175 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 322 | $9,596 |
| Tizanidine Hcl | 1,370 | $8,450 |
| Diclofenac Sodium | 496 | $7,520 |
| Cyclobenzaprine Hcl | 787 | $5,890 |
| Duloxetine Hcl | 469 | $5,587 |
| Amitriptyline Hcl | 443 | $3,200 |
| Baclofen | 228 | $2,935 |
| Gabapentin | 220 | $2,263 |
| Meloxicam | 820 | $1,936 |
| Trazodone Hcl | 409 | $1,518 |
| Celecoxib | 105 | $1,517 |
| Pregabalin | 41 | $1,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $349 | $175,40173 claims |
| Redhill Biopharma Inc.Movantik | $40 | $10,45326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 55 interventional pain medicine providers in Kentucky.
Other interventional pain medicine in Louisville
- Nathan LambornLouisville$10K
- Brandon SuttonLouisville$9K
- Gary ReasorLouisville$9K
- Kristal WilsonLouisville$9K
- Blake FechtelLouisville$6K
- Konrad KijewskiLouisville$6K
- Lady Christine Ong SioLouisville$5K
- Jeffrey BergLouisville$3K
- Aaron ComptonLouisville$3K
- Bill HaneyLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.